| 177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results | Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C | Journal of Nuclear Medicine | |
| 68Ga-PSMA PET/CT Revealing Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of Castration-Resistant Prostate Cancer. | Vadi SK, Kumar R, Mittal BR, Singh H, Singh SK. | Journal of Clinical Nuclear Medicine | |
| Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer. | Chaussé G, Abikhzer G, Probst S. | Journal of Clinical Nuclear Medicine | |
| Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. | Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D. | Oncotarget | |
| Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. | Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. | European Journal of Nuclear Medicine and Molecular Imaging | |
| 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning | Calais J, Czernin J, Cao M, Kishan A, Hegde J et al. | Journal of Nuclear Medicine | |
| Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control. | Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. | Journal of Nuclear Medicine | |
| Current status of theranostics in prostate cancer. | Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. | European Journal of Nuclear Medicine and Molecular Imaging | |
| Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. | von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. | European Journal of Nuclear Medicine and Molecular Imaging | |
| Prostate-specific membrane antigen theranostics: therapy with lutetium-177. | Ferdinandus J, Violet J, Sandhu S, Hofman MS | Current Opinion in Urology | |
